Optimization and Functional Effects of Stable Short Hairpin RNA Expression in Primary Human Lymphocytes via Lentiviral Vectors
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Specific, potent, and sustained short hairpin RNA (shRNA)-mediated gene silencing is crucial for the successful application of RNA interference technology to therapeutic interventions. We examined the effects of shRNA expression in primary human lymphocytes (PBLs) using lentiviral vectors bearing different RNA polymerase III promoters. We found that the U6 promoter is more efficient than the H1 promoter for shRNA expression and for reducing expression of CCR5 in PBLs. However, shRNA expression from the U6 promoter resulted in a gradual decline of the transduced cell populations. With one CCR5 shRNA this decline could be attributed to elevated apoptosis but another CCR5 shRNA that caused cytotoxicity did not show evidence of apoptosis, suggesting sequence-specific mechanisms for cytotoxicity. In contrast to the U6 promoter, PBLs transduced by vectors expressing shRNAs from the H1 promoter could be maintained without major cytotoxic effects. Since a lower level of shRNA expression appears to be advantageous to maintaining the shRNA-transduced population, lentiviral vectors bearing the H1 promoter are more suitable for stable transduction and expression of shRNA in primary human T lymphocytes. Our results suggest that functional shRNA screens should include tests for both potency and adverse metabolic effects upon primary cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector
Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., & Trono, D. (1996) · Science · doi:10.1126/science.272.5259.263 · Cited by 4,903 · cited 1×
“Among them, lentiviral vectors have the ability to transduce nondividing cells stably through integration of the vector DNA into the genome [10].”
BackgroundHOW CELLS RESPOND TO INTERFERONS
Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.227 · Cited by 3,932
Expression profiling reveals off-target gene regulation by RNAi
Jackson, A. L., Bartz, S. R., Schelter, J., Kobayashi, S. V., Burchard, J., Mao, M., Li, B., Cavet, G., & Linsley, P. S. (2003) · Nature Biotechnology · doi:10.1038/nbt831 · Cited by 2,370
A pancreatic islet-specific microRNA regulates insulin secretion
Poy, M. N., Eliasson, L., Krutzfeldt, J., Kuwajima, S., Ma, X., MacDonald, P. E., Pfeffer, S., Tuschl, T., Rajewsky, N., Rorsman, P., et al. (2004) · Nature · doi:10.1038/nature03076 · Cited by 2,102 · cited 1×
“Some miRNAs appear to play important roles in regulating differentiation and development processes at the posttranscriptional level [37,38].”
BackgroundRational siRNA design for RNA interference
Reynolds, A., Leake, D., Boese, Q., Scaringe, S., Marshall, W. S., & Khvorova, A. (2004) · Nature Biotechnology · doi:10.1038/nbt936 · Cited by 2,094
Zack, J. A., Arrigo, S. J., Weitsman, S. R., Go, A. S., Haislip, A., & Chen, I. S. Y. (1990) · Cell · doi:10.1016/0092-8674(90)90802-l · Cited by 1,517
Self-citationStable RNA interference: Comparison of U6 and H1 promoters in endothelial cells and in mouse brain
Mäkinen, P. I., Koponen, J. K., Kärkkäinen, A., Malm, T. M., Pulkkinen, K. H., Koistinaho, J., Turunen, M. P., & Ylä‐Herttuala, S. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.860 · Cited by 134
Cited by
Strategies for silencing human disease using RNA interference
Kim, D. H., & Rossi, J. J. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2006 · Cited by 1,078
Breaking down the barriers: siRNA delivery and endosome escape
Dominska, M., & Dykxhoorn, D. M. (2010) · Journal of Cell Science · doi:10.1242/jcs.066399 · Cited by 630
DiGiusto, D. L., Krishnan, A., Li, L., Li, H., Li, S., Rao, A., Mi, S., Yam, P., Stinson, S., Kalos, M., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000931 · Cited by 374
Artificial MicroRNAs as siRNA Shuttles: Improved Safety as Compared to shRNAs In vitro and In vivo
Boudreau, R. L., Martins, I., & Davidson, B. L. (2009) · Molecular Therapy · doi:10.1038/mt.2008.231 · Cited by 359
Grimm, D., Wang, L., Lee, J. S., Schürmann, N., Gu, S., Börner, K., Storm, T. A., & Kay, M. A. (2010) · Journal of Clinical Investigation · doi:10.1172/jci43565 · Cited by 196
“A link between shRNA dose and cytotoxicity is further supported by findings in cell culture, where stable high-level U6 shRNA expression was frequently less well tolerated than that from weaker promoters, such as H1 (9, 10).”
BackgroundKampmann, M., Bassik, M. C., & Weissman, J. S. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1307002110 · Cited by 123
“Furthermore, shRNAs can be expressed at levels that do not saturate the cellular RNAi machinery (27); this feature is an important prerequisite for maintaining knockdown ef fi ciency in the double-shRNA format, whereas siRNAs can cause side effects by saturating the cellular machinery (28).”
BackgroundAagaard, L. A., Zhang, J., von Eije, K. J., Li, H., Sætrom, P., Amarzguioui, M., & Rossi, J. J. (2008) · Gene Therapy · doi:10.1038/gt.2008.147 · Cited by 115
Metadata
- Authors
- An, D. S., Qin, F. X.-F., Auyeung, V. C., Mao, S. H., Kung, S. K. P., Baltimore, D., & Chen, I. S. Y.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2006-10
- Volume
- 14
- Issue
- 4
- Pages
- 494-504
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2125881252
- Cited by
- 155
- References
- 7
- FWCI
- 5.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.